Oral Soluble Guanylate Cyclase Stimulators Associated With Reduced Hospitalizations for Heart Failure

May 15-17, 2021; Virtual
In meta-analysis of 8 randomized placebo-controlled clinical trials, addition of oral sGC stimulators to guideline-directed medical therapy for heart failure reduced risk of hospitalization for heart failure vs placebo; net adverse events not significantly increased over placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 291 KB
Released: June 29, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Related Content

From AHA 2021, new analysis from the CHIEF-HF trial of canagliflozin vs placebo in patients with heart failure, as reported by Clinical Care Options (CCO)

Released: December 3, 2021

From AHA 2021, new analysis from EMPEROR-Preserved trial of empagliflozin in patients with “true” HFpEF, as reported by Clinical Care Options (CCO)

Released: December 2, 2021

From AHA 2021, new analysis of TRED-HF trial on detecting early relapse after HF, as reported by Clinical Care Options (CCO)

Released: December 2, 2021

From Clinical Care Options (CCO), new data in managing heart failure from ACC 2021

Lee R. Goldberg, MD, MPH, FACC James Udelson, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: July 28, 2021 Expired: July 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue